SHR-A1811 for HER2-positive recurrent or metastatic cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug, SHR-A1811, that targets a protein called HER2 found on some cervical cancer cells. It's for women whose cervical cancer has returned or spread and is not responding to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have cervical cancer that has come back or spread, and your tumor has the HER2 protein.
- You are willing to sign a consent form and follow the study schedule.
- You have not had untreated or active brain metastases.
- You do not have other active cancers, serious heart or lung problems, or a history of certain lung conditions.
- You agree to use birth control if you could become pregnant, and you are not breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new drug combination called SHR-A1811 can help people with cervical cancer that has come back or spread. It aims to find a better treatment option for those who have limited choices.
This study tests a new drug called SHR-A1811 in patients with advanced breast cancer that has a protein called HER2. The drug may help slow or stop cancer growth in patients who haven't had too many prior treatments.
This Phase 2 trial tests SHR-A1811, a cancer medicine, in people with advanced or returning cervical, ovarian, or endometrial cancer. It may help shrink tumors, depending on whether you meet study safety and eligibility requirements.
This trial tests a new drug, SHR-1811, combined with carboplatin for advanced breast cancer that has HER2 expression (including low levels). It is for people who have already tried standard treatments and their cancer has spread or cannot be removed by surgery.
This trial tests a new drug called SHR-A1811 in patients with advanced, incurable lung cancer that has a specific genetic change in the HER2 gene. The drug may help slow or stop cancer growth by targeting this genetic change.
This trial tests a drug called SHR-A1811 for women with HER2-positive breast cancer that did not shrink enough after 4 cycles of standard pre-surgery treatment. The goal is to see if this drug can help improve outcomes before surgery.
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.